E-Paper
Sun Pharma's Taro recalls over 17,000 units of antifungal shampoo in US amid safety concerns
The Class II recall, which began on December 9, addresses potential temporary health consequences from the product.
Taro Pharmaceutical Industries, a unit of Sun Pharma, is recalling over 17,000 units of an antifungal medication in the US due to manufacturing issues, according to the US Food and Drug Administration (USFDA).
According to its latest Enforcement Report, the US health regulator stated that Hawthorne-based Sun Pharma/ Taro is recalling 17,664 units of Ciclopirox Shampoo, an antifungal medication that treats seborrheic dermatitis, a condition that causes dry, flaky, and itchy skin.
The company is recalling the affected lot due to "Failed Impurity/Degradation specifications," the USFDA stated.
The company initiated the Class II nationwide recall on December 9 this year.
As per the USFDA, a Class-II recall is initiated when the use of, or exposure to, a violative product may lead to temporary or medically reversible health consequences, or when the likelihood of serious adverse health outcomes is minimal.
Sun Pharmaceutical Industries completed the merger of Taro Pharmaceutical Industries with itself in a deal valued at USD 347.73 million last year.
After the merger, Taro is now a private company and wholly owned by Sun Pharma.
Sun Pharma has been the majority shareholder of Taro since 2010.
Primarily focused on dermatology, Taro produces a wide range of prescription and over-the-counter products.
Indian pharmaceutical companies supply a substantial proportion of drugs to US residents, with four out of ten of all prescriptions filled in the US in 2022 being supplied by Indian companies.
